Cracking the code of advanced prostate cancer

Figure: age-adjusted cancer death rates per 100,000 U.S. men, by tumor site (American Cancer Society)For men in the U.S., prostate cancer is the second-leading cause of cancer death. Not all prostate...

A new line of attack on deadly prostate cancers

Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...

Cancer translated’s top blog posts of 2017

From basic science to survivorship and patient advocacy, the OHSU Knight Cancer Institute’s 'Cancer translated' blog explores new ideas and debates in cancer medicine. We sorted a year’s worth...

Solving the problem of drug-resistant cancer

To discover ways to prevent or delay resistance to cancer therapies, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt. The first successful targeted...

Check out the Knight Cancer pilot project award winners

Preventing skin cancer with a DNA-repair enzyme. Understanding how microRNAs modify cancer immunity. Using zebrafish embryos to rapidly assess toxicity of anticancer drug combinations. These are...

How to retarget cancers that have evaded targeted therapy

Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients,...

Breaking through the limits of cancer medicine

Gordon Mills, M.D., Ph.D., the new director of precision oncology at Oregon Health & Science University, outlines a vision for the field. Photo: Gordon Mills, M.D., Ph.D. (OHSU/Kristyna...

Radiation medicine’s evolving role in cancer care

(NCI/Rhoda Baer) Expanding treatment options for breast cancer. Enhancing immunotherapy. Addressing disparities in access to cutting-edge treatment. These are some of the highlights from ASTRO,...